RYR2 and cardiac arrhythmia: Creating CRISPR/Cas9-gene-edited mutations in control hiPSC-CMs or generating hiPSC-CMs directly from the fibroblasts of patients that express the mutation [16,17,24], isolated cells from mutant mice hearts carrying the mutation [8,9,25,26] or HEK293 cell lines transfected with recombinant mutant RyR2 proteins [10,11,27] are the platforms generally used for studying CPVT1 arrhythmia.